Improving target volume delineation for 3D image-based dosimetry in PRRT
Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is currently the most effective molecular radiotherapy (MRT) treatment for patients who suffer from neuroendocrine tumours (NET) with metastasised disease. In PRRT the treatment is systemic and the most frequent treatment protocol is to administer 7.4GBq of Lu-177 up to four times with a six to […]
Dr Emiliano Spezi, Dr Salvatore Berenato
Cardiff University, Velindre Cancer Centre